Martine Rothblatt, the Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), sold company shares totaling $5.5 million on April 13, 2026. The divestiture occurred across several transactions and involved 9,495 shares of common stock, with sale prices spanning from $569.7771 to $579.526 per share.
On the same day, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, for a reported total value of $1,387,285.
Both the sales and the option exercise were performed under a pre-arranged 10b5-1 trading plan Rothblatt adopted on November 7, 2025. The plan authorizes the exercise of up to 1,734,410 stock options that expire on March 17, 2027, and remains in effect until the earlier of that expiration date or December 31, 2026.
Following these transactions, Rothblatt is recorded as directly owning 40,513 shares of United Therapeutics common stock. In addition to direct holdings, indirect ownership is listed as 166 shares held by spouse and multiple trusts holding 324,518; 258,117; 45,596; and 10,962 shares, respectively.
United Therapeutics, with a market valuation of $25.28 billion, reports gross profit margins of 88%.
Recent company developments
United Therapeutics has been active beyond insider transactions. The company announced that its investigational liver assist device, miroliverELAP, received the Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration. The device is intended to provide temporary liver support for patients experiencing acute liver failure.
Analyst attention on the company has intensified in parallel with clinical progress. Raymond James initiated coverage with an Outperform rating and a $700 price target, citing the potential for Tyvaso to capture meaningful sales in idiopathic pulmonary fibrosis. H.C. Wainwright raised its price target to $660 while maintaining a Buy rating and pointing to positive data from the TETON-1 trial for Tyvaso. BofA Securities lifted its price target to $626 following encouraging Phase 3 trial results, and Jefferies adjusted its price target to $733, reflecting increased confidence in the company’s indications for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
What the filings show
- Insider sale: 9,495 shares disposed at prices between $569.7771 and $579.526 on April 13, 2026, totaling $5.5 million in proceeds.
- Option exercise: 9,500 shares acquired at $146.03 per share on April 13, 2026, totaling $1,387,285.
- 10b5-1 plan: Adopted November 7, 2025; covers up to 1,734,410 options expiring March 17, 2027 and in force until that expiration or December 31, 2026, whichever comes first.
- Reported ownership: 40,513 shares directly owned by Rothblatt; additional indirect holdings via spouse (166) and several trusts (324,518; 258,117; 45,596; 10,962).
These disclosures come amid a backdrop of regulatory recognition for a liver-support device and multiple analyst price-target increases tied to clinical outcomes for Tyvaso. The filings document the mechanics of Rothblatt’s transactions and the governance framework under which they were executed, while the company’s recent clinical and regulatory developments continue to draw market and analyst attention.